MLchartDataset catalogue

Lutetium Lu 177 XT117

Term · Oncology and biomedicine · MLC-T-ONC-014926

A radioconjugate composed of XT117, a fibroblast activation protein inhibitor (FAPi), conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against FAP-expressing cancer-associated fibroblasts (CAFs). Upon administration, lutetium Lu 177 XT117 targets and binds to FAP-expressing CAFs. Upon binding, FAP-expressing CAFs are destroyed by 177Lu through the specific delivery of beta particle radiation. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME) of various cancers.

Table 1. Record
IdentifierMLC-T-ONC-014926
FieldOncology and biomedicine
Synonyms177Lu-labeled XT117; [177Lu]Lu-XT117; Lu-177-XT117
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-014926",
  "term": "Lutetium Lu 177 XT117",
  "field": "Oncology and biomedicine",
  "definition": "A radioconjugate composed of XT117, a fibroblast activation protein inhibitor (FAPi), conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against FAP-expressing cancer-associated fibroblasts (CAFs). Upon administration, lutetium Lu 177 XT117 targets and binds to FAP-expressing CAFs. Upon binding, FAP-expressing CAFs are destroyed by 177Lu through the specific delivery of beta particle radiation. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME) of various cancers.",
  "synonyms": [
    "177Lu-labeled XT117",
    "[177Lu]Lu-XT117",
    "Lu-177-XT117"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-xt117/"
}

Record 10,408 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.